Kornimate/medical-research-clean huggingface dataset:
effect of laser photobiomodulation therapy on chronic pain and opioid weaning

Conditions: Chronic Pain

Summary: this study will examine the effect of laser photobiomodulation therapy on pain and opioid pain medication weaning on patients who are undergoing opioid pain medication weaning.

the primary objective of this study is to determine if treatment with laser photobiomodulation therapy reduces pain and facilitates opioid pain medication (opm) reduction (weaning). the subject group includes patients with chronic pain who are undergoing opm weaning and are candidates for laser photobiomodulation therapy. this is a prospective interventional study using a double-blind 4-period crossover design to assess the efficacy of high power laser photobiomodulation therapy compared to sham (low power laser) therapy in reducing pain and improving compliance with opm weaning.

Eligibility criteria:
inclusion criteria: * age 18 or older. * taking prescribed opioid pain medications in an amount in excess of 30 morphine equivalent dose (med) for 6 months or longer. * have been recommended to wean or reduce their med. * medically stable such that subject does not have unstable angina, copd requiring supplemental oxygen, untreated or active cancer or similar conditions that would make participation difficult or unsafe. * compliant with all physician recommendations relating to medication usage. * ambulatory and able to use the toilet independently. * negative pregnancy test in subjects of childbearing potential * willing to attempt opioid pain medication taper. * competent to provide informed consent. * capable of understanding and completing study questionnaires. * subject willing to participate in the study for up to 12 weeks. exclusion criteria: * not capable of understanding or completing study questionnaires. * lacking capacity to provide fully informed consent. * substance use disorder not in remission. * considering surgery or other invasive procedures that would take place during the study. * used isotretinoin (accutane) within 6 months prior to study enrollment * cancer not in remission. * need of ongoing transcutaneous electrical nerve stimulation (tens) therapy, massage therapy, chiropractic care or other treatments intended to remediate pain other than treatment in the sharp pain program. * a female who is pregnant or lactating, or of childbearing potential unless a medically acceptable method of birth control is in use. * any use of light-activated drugs (photodynamic therapy) or heat sensitive medications within 30 days of first treatment. * used an investigational drug/device therapy or participated in any clinical investigation relating to pain within 4 weeks prior to study enrollment. * a psychiatric or psychological condition that would place undo stress on the subject, prevent full participation or compromise data collection. * the subject is otherwise determined, based on the opinion of the investigator, to be an unsuitable candidate for enrollment in this study
treatment of sodium retention in liver cirrhosis with dexamethasone

Conditions: Liver Cirrhosis

Summary: accumulation of salt and water in patients with liver disease (so called liver cirrhosis) is possibly related to the increased effect of steroid hormones on salt reabsorption in the kidney. by reducing overall steroid production with the dexamethasone the accumulation of salt and water could be prevented.


Eligibility criteria:
inclusion criteria: * patients with established liver cirrhosis (biopsy or biochemically) * hepatorenal syndrome type 1 or 2 (with a serum creatinin \>175 umol/l) * age between 18 and 75 * no bacterial infection * no cardiovascular or extrahepatic disease (end of life) * no structural kidney disease * no hepatocellular carcinoma exclusion criteria: * age under 15 or over 75 * treatment with corticosteroids (dexamethasone included) * bacterial infection * cardiovascular or extrahepatic disease (end of life) * structural kidney disease (indicated by hematuria, proteinuria) * hepatocellular carcinoma * mental disability

Keywords: dexamethasone sodium
endothelial glycocalyx in patients with chronic kidney disease

Conditions: Healthy; Chronic Kidney Diseases

Summary: the luminal side of the entire vasculature is covered with a gel-like polymer called endothelial glycocalyx (eg). eg is important for the transport of molecules in and out of the blood cells and for endothelial function. eg protects the blood vessel wall, is likely to contribute to maintenance of normal blood pressure and the prevention of blood clot formation. overall it is likely to avoid development of cardiovascular disease. a newly developed blood test, salt-blood test, can measure erythrocyte salt sensitivity and gives information about the condition of eg. eg can also be measured by release of endothelial glycocalyx proteins. previous studies indicate that this eg is impaired by a number of chronic diseases, including chronic kidney disease. this study investigates the quality of glycocalyx in patients with chronic kidney disease, and compares with the layer in healthy.

the purpose of this study is to gain knowledge about how pronounced the eg are affected in varying degrees of chronic kidney disease compared with healthy controls assessed by 1. salt-blood test 2. release of endothelial glycocalyx proteins. and to see how this correlates to 1. blood pressure (peripheral and central) 2. pulse wave velocity 3. albuminuria 4. coagulation system 5. vasoactive hormones (prc, p-ang-ii, p-aldo, p-anp, p-bnp, p-avp)

Eligibility criteria:
inclusion criteria patients with chronic kidney disease: ckd i-v age\> 18 years 4 diabetics in each ckd-class dialysis patients must have received dialysis for at least 3 months. signed consent exclusion criteria, patients with chronic kidney disease: nephrotic syndrome (u-alb\> 3.5 g / d, p-alb \<30 g / l, and peripheral edema) alcohol abuse drug abuse pregnancy and lactation hbg \<6.2 mmol / l inclusion criteria, healthy people: both gender signed consent exclusion criteria, healthy people: arterial hypertension heart, lung, liver, kidney, endocrine og cerebral diseases alcohol, drug or medical abuse smoking pregnancy or breastfeeding blood-donation within a month clinically significant abnormalities in ecg, blood samples or urine samples

Keywords: salt blood test endothelial glycocalyx chronic kidney disease syndecan-1 heparan sulfate
dna repair in patients with stable angina.

Conditions: Coronary Artery Disease; Coronary Arteriosclerosis; DNA Damage; DNA Repair Abnormality

Summary: markers of dna damage and repair are present in both atherosclerotic plaques and peripheral blood mononuclear cells of patients with coronary artery disease. a positive correlation has been observed between the level of dna damage and the severity of atherosclerotic lesions, as well as atherogenic risk factors such as smoking, hypertension and hyperlipidaemia. a number of in-vitro studies have implicated defective dna repair in the development and progression of atherosclerotic lesions. in mouse models of atherosclerosis, the dna repair signalling cascade has been shown to be amenable to pharmacological intervention and overexpression of specific repair proteins attenuate the development of atherosclerotic plaques. however, data regarding the role of dna repair in the pathogenesis of atherosclerosis in humans are lacking. we have preliminary data indicating reduced dna repair activity in patients with stable angina. this study will determine the molecular basis and the biological consequences of this observation.


Eligibility criteria:
inclusion criteria: * age ≥18 years * ability to provide written informed consent exclusion criteria: * age ≥ 80 years * inability to provide written informed consent * presentation with an acute coronary syndrome * severe valvular heart disease * hypertrophic cardiomyopathy * left ventricular ejection fraction ≤ 35% * prior coronary revascularisation (surgical or percutaneous) * diabetes mellitus * clinical evidence of peripheral vascular disease * prior history of cerebrovascular disease * malignancy * active inflammatory disorders (e.g. rheumatoid arthritis/connective tissue disorder) * renal impairment egfr \<60ml/min/1.73m2 * anaemia (hb \<100g/dl)
continuous intraocular pressure (iop) measurement and ability to detect treatment effect

Conditions: Glaucoma; Ocular Hypertension

Summary: continuous intraocular pressure (iop) measurement with a contact lens sensor may provide more information on the drug-related iop change than 24-hour iop measurement with goldmann applanation tonometry (gat.

* participants are washed ot from all glaucoma medication for 6 weeks * one eye per participant is investigated (study eye) * 24-h intraocular pressure (iop) curve is obtained with goldmann tonometry and sensimed contact lens sensor tonometry twice, in 14 days * for sensimed contact lens curves median values (in arbitrary units), for goldmann applanation tonometry, mean and sd values are used to characterize the curves, for comparisions % changes are used for the corresponding time periods * treatment (travoprost 0.005% 1/day) is given to all eyes for 3 months 24-h goldmann and sensimed iop curves are repeated * iop curves are determined in arbitrary units and mmhg, respectively, and compared for reproducibility (untreated phase) and relative (%)change (untreated curve vs. under treatment curve) with both methods, respectively

Eligibility criteria:
inclusion criteria: * primary open-angle glaucoma (poag), ocular hypertension(oht) * 18 years or older * c/d \<= 0.7 * no risk for visual field damage * iop \> 22 mmhg exclusion criteria: * pregnancy and lactation * known intolerance to travoprost, topical anesthetic * previous ocular surgery at any time * previous ocular laser treatment within 1 year

Keywords: intraocular pressure
cortical bone trajectory screws vs. traditional pedicle screws fixation

Conditions: Spinal Stenosis Lumbar; Lumbar Disc Herniation; Intervertebral Disc Degeneration

Summary: transforaminal lumbar interbody fusion (tlif) had been favorable for effectively decrease pain and disability in specific spinal disorders; however, there has been concern regarding pedicle screw placement during tlif surgery. recently, several biomechanical studies had demonstrated that cbt technique achieves screw purchase and strength equivalent to or greater than the traditional method. furthermore, only 1 report examined the surgical outcomes of tlif with cbt screws fixation compared with tlif using traditional pedicle screws fixation. tlif with cbt screws fixation may be effective for specific spinal disorders, but the evidence supporting this possibility is still limited.

methods and analysis: blinded randomized controlled trial (rct) will be conducted. a total of 108 participants will be randomly allocated to either a cbt-tlif group or a ps-tlif group at a ratio of 1:1. the primary clinical outcome measures are: change in back and lower limb pain with visual analogue scale (vas) and change in quality adjusted life years (qaly) will be assessed by eq-5d-5l. measurements will be carried out at five fixed time points (pre-operatively and at 3, 6, 12 and 24 months). ethics and dissemination: the study had been reviewed and approved by the ethics committee of the second affiliated hospital of the wenzhou medical university, wenzhou, china(batch:2017-03). the results will be presented in peer-reviewed journals and related website within 2 years after the last operation.

Eligibility criteria:
inclusion criteria: 1. age of at least 18 years; 2. all of participants will be informed consent; 3. chronic low back pain (visual analogue scale at least 3 out of 10 at rest and at least 5 out of 10 under physical strain) after having failed conservative treatment for 6 months; 4. single-segment lower lumbar vertebral disease (including lumbar spinal cannal stenosis, foraminal stenosis, segmental instability, lumbar disc herniation, and painful disc degeneration (back disc); exclusion criteria: 1. serious deformity of lumbar vertebrae; 2. dysplasia of lumbar pedicle or vertebral laminar; 3. obvious osteoporosis of lumbar vertebrae; 4. metabolic bone diseases such as osteomalacia or paget's disease; 5. spondylolisthesis \> grade 2 (meyerding); 6. caudaequina injury or severe radiculopathy; 7. post inflammatory instability of the vertebral spine; 8. body mass index \> 30; 9. immunologic diseases or metabolic syndrome; 10. therapy with systemic corticosteroids or immunosuppressants; 11. current using coumadin (or warfarin) or heparin therapy for more than 6 months at the time of operation.

Keywords: cbt rct tlif
rollover study of weekly paclitaxel (bms-181339) in patients with head and neck cancer

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (ca139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects


Eligibility criteria:
inclusion criteria: * subjects with advanced head and neck cancer who have completed the previous late phase 2 study (ca139-388) and should have continued therapy with paclitaxel as the discretion of the investigator
effect of osa on rv heamodynamics and function

Conditions: Sleep Apnea, Obstructive

Summary: correlation of severity of obstructive sleep apnea and function of the right ventricle by means of 2d echocardiography and cardiac mri

obstructive sleep apnea (osa) is a frequently under diagnosed condition that has emerged as an increasing medical problem with important social and financial implications worldwide. osa is a well established risk factor for systemic hypertension , myocardial infarction or stroke. obstructive sleep apnea syndrome (osas) is characterized by repetitive collapse of the upper airway during sleep .the obstructive apneic event is associated with considerable breathing efforts against a totally or partially occluded upper airway, and apnea is terminated by an arousal and heavy snoring as airflow is restored. severity of osas is described according to total number of apneas and hyperpneas per hour of sleep, which is named as the apnea-hypopnea index (ahi). cardiovascular disturbances are the most serious complications of osas. these complications include heart failure, acute myocardial infarction, nocturnal arrhythmias, stroke, systemic and pulmonary hypertension. all these cardiovascular complications increase morbidity and mortality of osas. currently, sleep apnea is accepted as one of the identifiable causes of hypertension. also, osas is closely associated with obesity and ageing. there is conclusive evidence that osas influences right heart function (the pathophysiological consequences of sleep apnea-hypopnea might result in an imbalance in myocardial oxygen delivery/consumption ratio, activation of sympathetic and other neurohormonal systems, and increased right and left ventricular after load )

Eligibility criteria:
inclusion criteria: * subjects diagnosed as osa with age range from 18 to 70 years * glomerular filtration rate (mdrd formula-based) \> 60 ml/min * arterial hypertension diagnosed according to the european society of hypertension 2013 guidelines. exclusion criteria: * mental illness * acute and chronic inflammation * heart failure iii or iv grade * chronic administration of drugs with confirmed nephrotoxicity and/or sympathicomimetics * obstructive and restrictive pulmonary diseases which may deteriorate the function of the respiratory system
the importance of delayed cord clamping

Conditions: Newborn; Vitality; Iron Deficiency Anemia

Summary: after birth, the umbilical cord is usually clamped and separated from the placenta within the first 30 seconds. although the exact time to clamp the umbilical cord is unknown, allowing placental transfusion after birth has many benefits for the newborn. increased bleeding control, which is reported as a maternal complication, has not been found in studies. approximately 28ml/kg additional blood volume is transferred to the baby with placental transfusion. the hemodynamics of the newborn are positively affected as the blood volume increases the right ventricular volume and the pulmonary pressure begins to decrease with the first breath. in addition, due to this additional blood volume, stem cells and erythrocytes pass through more. there are studies showing that it reduces iron deficiency that occurs in infants at the 4th month. in our study, we aimed to examine the effect of allowing placental transfusion until cord pulsation stopped and the effect of delayed cord clamping on iron deficiency at the 4th month in babies.

healthy term newborns who will be born in our gynecology clinic; type of birth, week of gestation, birth weight, cord clamping time, cord blood gas, apgar score, complete blood count, maternal complete blood count, maternal complications, baby's first body temperature, postnatal day 3 hematocrit and bilirubin level, diet, phototherapy treatment application measurements will be determined and evaluated in terms of the baby's condition, monthly routine baby follow-up (anthropometric measurements and physical examination), and routine 4th month iron deficiency screening. these measurements and applications will be made by the baby nurse, pediatric assistant and pediatrician who will be present during the birth.

Eligibility criteria:
inclusion criteria: * the healthy babies of healthy mothers (no pre-eclampsia, no diabetes, no prolonged rupture of membranes or signs of infection) term (gestational age ≥ 37 weeks) and no additional abnormality were included in the study. exclusion criteria: * . babies who needed resuscitation were excluded from the study

Keywords: delayed cord clamping hypothermia polycythemia iron deficiency anemia
clinical evaluation of the fluidvision accommodating intraocular lens (aiol)

Conditions: Aphakia

Summary: the purpose of this study is to evaluate the safety and effectiveness of an investigational iol.

eligible subjects will receive the investigational iol in one eye and be followed at 1 day, 1 week, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months and 36 months post-operation.

Eligibility criteria:
key inclusion criteria: * eligible for primary intraocular lens implantation for the correction of aphakia following cataract extraction; * best corrected distance visual acuity worse than 20/40 either with or without a glare source present (e.g. brightness acuity tester); * less than or equal to 1.0 diopter (d) of preoperative keratometric astigmatism; * willing and able to comply with schedule for follow-up visits for 36 months after surgery. * other protocol-defined inclusion criteria may apply. key exclusion criteria: * systemic disease that could increase the operative risk or confound the outcome (e.g. autoimmune disease, diabetes); * taking systemic medications that may confound the outcome or increase the risk to the subject; * ocular conditions that may predispose for future complications; * previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject; * pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes; * diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future best corrected visual acuity loss worse than 20/40. * other protocol-defined exclusion criteria may apply.

Keywords: cataract
effect of a newly developed brace on foot biomechanics.

Conditions: Healthy

Summary: for this interventional study the investigators will recruit a number of healthy volunteers with no symptoms in their lower limbs in the past 6 months and without history of foot and/or ankle conditions and/or surgery. these volunteers will undergo a single dynamic computerized tomography scan session before and after the support is carried, to find out if there is a change in the kinematics of the foot. the results will be analyzed statistically.

for this study the investigators will recruit 15 healthy volunteers who will be undergone a single dynamic computed tomography (4dct) scanning session before and after wearing a brace, in order to find out if there is a change in foot kinematics. between the two scans, the subjects will wear the brace and walk for 1 minute. data collected with the 4dct will be processed to get 3d imaging of the subtalar and midtarsal joints, needed to quantify the rotations in the three planes of the space (cardan angles).

Eligibility criteria:
inclusion criteria: * healthy volunteers; * 18\<age\<60; * no gender restrictions; exclusion criteria: * symptoms in their lower limbs in the past 6 months * history of foot and/or ankle conditions and/or surgery * pregnancy

Keywords: ankle brace fasciitis, plantar dynamic computed tomography subtalar joint kinematics
study on prognosis of acute-on-chronic liver failure complicated by bacterial or fungal infection

Conditions: Acute-On-Chronic Liver Failure

Summary: the subjects of this study were inpatients with aclf who were admitted to tongji hospital in wuhan from march 2023 to june 2025. after patients were enrolled, the patient's general information (gender, age, past medical history, etc.), complications (ascites, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, etc.), laboratory tests (crp, pct, inr, wbc, fungal/bacterial diagnostic tests, etc.), symptoms and signs at the time of infection, and at admission (d1), d4, d7, d14, d21, etc.) were recorded save the blood separately. the patients were divided into fungal infection group, bacterial infection group and non-infection group according to the infection status after admission.


Eligibility criteria:
inclusion criteria: 1. tbil ≥ 12 mg/ml and inr ≥ 1.5 2. chronic hepatitis b exclusion criteria: (1) \ 80 years old; (2) primary hepatic or extrahepatic carcinoma; (3) with severe diseases of other organs or systems; (4) pregnancy; (5) imcomplete information
a study of brentuximab vedotin in relapsed or refractory non-hodgkin lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell

Summary: this is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with cd30-positive non-hodgkin lymphoma (nhl) (part a). the study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) (part b) as well as further evaluate correlation of cd30 expression and response in dlbcl (part c).


Eligibility criteria:
inclusion criteria: * histologically-confirmed nhl (dlbcl only for parts b and c) * relapsed or refractory disease following at least 1 prior systemic therapy * measurable disease of at least 1.5 cm as documented by ct * eastern cooperative oncology group (ecog) performance status less than or equal to 2 exclusion criteria: * history of another primary invasive malignancy that has not been in remission for at least 3 years * current diagnosis of systemic or cutaneous anaplastic large cell lymphoma or mycosis fungoides * b cell lymphoma previously treated with only single-agent rituximab (for patients receiving brentuximab vedotin only) or corticosteroids as monotherapy * known cerebral/meningeal disease

Keywords: lymphoma, large b-cell, diffuse antigens, cd30 antibody-drug conjugate antibodies, monoclonal lymphoma, non-hodgkin monomethyl auristatin e drug therapy immunotherapy hematologic diseases lymphoma lymphoma, b-cell lymphoma, t-cell